Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept)

被引：20
|
作者：
Yazisiz, V. [1 ]
Avci, A. B. [1 ]
Erbasan, F. [1 ]
Yildirim, B. [2 ]
Terzioglu, E. [1 ]
机构：
[1] Akdeniz Univ, Sch Med, Div Rheumatol, Dept Internal Med, TR-07058 Antalya, Turkey
[2] Akdeniz Univ, Sch Med, Div Gastroenterol, Dept Internal Med, TR-07058 Antalya, Turkey
来源：
COLORECTAL DISEASE | 2008年 / 10卷 / 09期
关键词：
D O I：
10.1111/j.1463-1318.2008.01490.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Inhibition of tumour necrosis factor (TNF)-alpha is effective in the treatment of rheumatoid arthritis and other inflammatory rheumatic diseases. Anti-TNF antibodies such as infliximab, etanercept and adalimumab are commonly used. There are structural and functional differences among these agents. We describe development of Crohn's disease in a patient with ankylosing spondylitis receiving anti-TNF therapy. This case suggests that the appearance of gastrointestinal symptoms in patients on anti-TNF therapy must be evaluated to find out whether this is a new onset or an exacerbation of underlying inflammatory bowel disease.
引用
收藏
页码：953 / 954
页数：2
相关论文
共 50 条
  • [1] Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy
    Helbling, D
    Breitbach, TH
    Krause, M
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (12) : 1393 - 1395
  • [2] Anti-tumour necrosis factor (TNF)-α therapy (etanercept)
    Maya Buch
    [J]. Arthritis Research & Therapy, 4 (1)
  • [3] Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
    van Deventer, SJH
    [J]. GUT, 2002, 51 (03) : 362 - 363
  • [4] Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease
    Mak, Joyce Wing Yan
    Tang, Whitney
    Yip, Terry Cheuk Fung
    Ran, Zhi Hua
    Wei, Shu Chen
    Ahuja, Vineet
    Kumar, Sudheer
    Leung, Wai Keung
    Hilmi, Ida
    Limsrivilai, Julajak
    Aniwan, Satimai
    Lam, Belsy C. Y.
    Chan, Kam Hon
    Ng, Ka Man
    Leung, Chi Man
    Li, Michael K. K.
    Lo, Fu Hang
    Sze, Alex Shun Fung
    Tsang, Steven Woon Choy
    Hui, Aric J.
    Hartono, Juanda Leo
    Ng, Siew C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (11-12) : 1195 - 1203
  • [5] Anti-tumour necrosis factor-α therapies in Crohn's disease
    Sprakes, M. B.
    Hamlin, P. J.
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (11) : 644 - 647
  • [6] Effects of anti-tumour necrosis factor-α therapy on the quality of life in Crohn's disease
    Van Balkom, BPJ
    Schoon, EJ
    Stockbrügger, RW
    Wolters, FL
    Van Hogezand, RA
    Van Deventer, SJH
    Oldenburg, B
    Van Dullemen, HM
    Russel, MGVM
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (06) : 1101 - 1107
  • [7] The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease
    Greener, Tomer
    Boland, Karen
    Steinhart, A. Hillary
    Silverberg, Mark S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 (04): : 458 - 464
  • [8] Anti-tumour necrosis factor therapy improves initial resection rates in Crohn's disease
    Kanmura, S.
    Numata, M.
    Fujita, H.
    Ohi, H.
    Kodama, M.
    Tokushige, K.
    Ido, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S300 - S301
  • [9] Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease
    Mattoo, Vandita Y.
    Basnayake, Chamara
    Connell, William R.
    Ding, Nik
    Kamm, Michael A.
    Lust, Mark
    Niewiadomski, Ola
    Thompson, Alexander
    Wright, Emily K.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (03) : 249 - 266
  • [10] Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease
    Fanning, Scott B.
    Chapman, Grace
    Yau, Yunki
    Leong, Rupert W. L.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (01) : 215 - 215
12345